Back to News
Market Impact: 0.25
Bayer's Phase 3 REVEAL Study Of I 124 Evuzamitide Meets Primary Goals In Cardiac Amyloidosis
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsTechnology & Innovation
Bayer reported Phase III REVEAL study results for its investigational PET radiotracer iodine 124 evuzamitide (I 124 evuzamitide) in the diagnosis of cardiac amyloidosis. The study met its primary endpoint (details not included in the excerpt), supporting the clinical validity of the diagnostic. This is likely supportive for sentiment around Bayer’s pipeline but, with limited disclosed metrics, should be a modest price mover.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
BAYRY0.40
More News
- CoreWeave credit default swaps hit distress levels as investors sour on AI debt
- Penske Automotive agrees to be taken private by Penske, Mitsui
- Supermicro promised a new CFO in December 2024. A $2.5 billion smuggling case and a co-founder’s arrest later, it has one
- Blackstone President Jon Gray Bets Big on AI Boom
- What's behind the sell-off in AI neocloud stocks like CoreWeave and Nebius
- Giant Taiwanese chipmaker TSMC confirms it’s in talks with Elon Musk to join ‘Terafab’ complex in Texas: ‘The AI market continues to be very strong’